SAR446597

PreclinicalSmall molecule

Sanofi

SAR446597 is one of 68 small molecule programs targeting Geographic Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyRecruiting

Age-Related Macular DegenerationActive, not recruiting

Geographic AtrophyPreclinical

Recruiting

Age-Related Macular DegenerationPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Eylea

Regeneron

Phase 3

44 2

Lucentis

Roche

Phase 3

64 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 10

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

PreclinicalRecruiting

Geographic Atrophy

NCT07215234

Clinical

Trials by Indication[1]

Geographic Atrophy1 trial

A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT07215234·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAR446597. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR446597 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR446597. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Sanofi

SAR446597

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Geographic Atrophy1 trial

References

Drug Info

Quick Facts

Related News